CVE:ACST - Acasti Pharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
C$1.42 +0.01 (+0.71 %)
(As of 03/20/2019 06:03 AM ET)
Previous CloseC$1.41
Today's RangeC$1.40 - C$1.44
52-Week RangeC$0.57 - C$2.29
Volume36,327 shs
Average Volume68,081 shs
Market CapitalizationC$110.94 million
P/E Ratio-1.36
Dividend YieldN/A
BetaN/A
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Receive ACST News and Ratings via Email

Sign-up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-450-6864555

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowC$0.58 per share
Book ValueC$0.39 per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$110.94 million
Next Earnings DateN/A
OptionableNot Optionable

Acasti Pharma (CVE:ACST) Frequently Asked Questions

What is Acasti Pharma's stock symbol?

Acasti Pharma trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ACST."

Has Acasti Pharma been receiving favorable news coverage?

News articles about ACST stock have been trending positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Acasti Pharma earned a news impact score of 2.1 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the next few days.

Who are some of Acasti Pharma's key competitors?

What other stocks do shareholders of Acasti Pharma own?

Who are Acasti Pharma's key executives?

Acasti Pharma's management team includes the folowing people:
  • Ms. Janelle D' Alvise, Pres, CEO & Director
  • Dr. Pierre Lemieux, Chief Operating Officer
  • Mr. Jean-François Boily, VP of Fin.
  • Mr. Brian James Groch, Chief Commercial Officer (Age 52)

How do I buy shares of Acasti Pharma?

Shares of ACST and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Acasti Pharma's stock price today?

One share of ACST stock can currently be purchased for approximately C$1.42.

How big of a company is Acasti Pharma?

Acasti Pharma has a market capitalization of C$110.94 million.

What is Acasti Pharma's official website?

The official website for Acasti Pharma is http://www.acastipharma.com/.

How can I contact Acasti Pharma?

Acasti Pharma's mailing address is 545 Prom du Centropolis Suite 100, LAVAL, QC H7T 0A3, Canada. The company can be reached via phone at +1-450-6864555.


MarketBeat Community Rating for Acasti Pharma (CVE ACST)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  89 (Vote Underperform)
Total Votes:  190
MarketBeat's community ratings are surveys of what our community members think about Acasti Pharma and other stocks. Vote "Outperform" if you believe ACST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACST will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/20/2019 by MarketBeat.com Staff

Featured Article: What is systematic risk?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel